Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval | Morningstar

Retrieved on: 2024-05-29 10:54:38

Tags for this article:

Acquired hemolytic anemia

Blood disorders

Alexion Pharmaceuticals

Hemolytic–uremic syndrome

Thrombotic microangiopathy

Hematologic disease

Paroxysmal nocturnal hemoglobinuria

Amgen

Soliris

Click the tags to see associated articles and topics

Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval | Morningstar. View article details on hiswai:

Excerpt

Soliris, developed by AstraZeneca (AZN)-owned Alexion Pharmaceuticals, is approved for the same treatment indications. In patients with paroxysmal ...

Article found on: www.morningstar.com

View Original Article